GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Recbio Technology Co Ltd (HKSE:02179) » Definitions » EV-to-EBITDA

Jiangsu Recbio Technology Co (HKSE:02179) EV-to-EBITDA : -7.11 (As of Jun. 02, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Jiangsu Recbio Technology Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Jiangsu Recbio Technology Co's enterprise value is HK$3,849.96 Mil. Jiangsu Recbio Technology Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-541.40 Mil. Therefore, Jiangsu Recbio Technology Co's EV-to-EBITDA for today is -7.11.

The historical rank and industry rank for Jiangsu Recbio Technology Co's EV-to-EBITDA or its related term are showing as below:

HKSE:02179' s EV-to-EBITDA Range Over the Past 10 Years
Min: -115.16   Med: 0   Max: 0
Current: -7.5

HKSE:02179's EV-to-EBITDA is ranked worse than
100% of 449 companies
in the Biotechnology industry
Industry Median: 9.63 vs HKSE:02179: -7.50

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-02), Jiangsu Recbio Technology Co's stock price is HK$8.39. Jiangsu Recbio Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.301. Therefore, Jiangsu Recbio Technology Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Jiangsu Recbio Technology Co EV-to-EBITDA Historical Data

The historical data trend for Jiangsu Recbio Technology Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Recbio Technology Co EV-to-EBITDA Chart

Jiangsu Recbio Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - - -13.86 -9.31

Jiangsu Recbio Technology Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial - -24.08 -13.86 - -9.31

Competitive Comparison of Jiangsu Recbio Technology Co's EV-to-EBITDA

For the Biotechnology subindustry, Jiangsu Recbio Technology Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Recbio Technology Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Jiangsu Recbio Technology Co's EV-to-EBITDA falls into.



Jiangsu Recbio Technology Co EV-to-EBITDA Calculation

Jiangsu Recbio Technology Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3849.963/-541.398
=-7.11

Jiangsu Recbio Technology Co's current Enterprise Value is HK$3,849.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jiangsu Recbio Technology Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-541.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Recbio Technology Co  (HKSE:02179) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Jiangsu Recbio Technology Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.39/-1.301
=At Loss

Jiangsu Recbio Technology Co's share price for today is HK$8.39.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jiangsu Recbio Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.301.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Jiangsu Recbio Technology Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Jiangsu Recbio Technology Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Recbio Technology Co (HKSE:02179) Business Description

Traded in Other Exchanges
N/A
Address
No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN
Jiangsu Recbio Technology Co Ltd is an vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. Company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Executives
Feng Tao 2201 Interest of corporation controlled by you
Bei Jing Jun Lian Cheng Yuan Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Zhu Linan 2201 Interest of corporation controlled by you
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Cheng He Zhong Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Jun Lian Jie You Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hui Zhi Yi Hao Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Chen Hao 2201 Interest of corporation controlled by you
La Sa Jun Qi Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Chao Rui Yi Yao Ke Ji He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Lyfe Capital Fund Iii (dragon), L.p.
Liu Yong
Chen Wei 2201 Interest of corporation controlled by you
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you

Jiangsu Recbio Technology Co (HKSE:02179) Headlines

No Headlines